From a safety standpoint, retatrutide's known adverse effect profile from phase II trials includes: Nausea, vomiting, and diarrhoea (gastrointestinal effects common to GLP-1 receptor agonists) Reduced appetite and potential nutritional deficiencies with prolonged use Elevated heart rate observed in some trial participants Pancreatitis and gallbladder disease , which are recognised class cautions for GLP-1based therapies and should be considered in the context of retatrutide, although retatrutide-specific data remain limited Thyroid C-cell changes , observed in rodent studies with GLP-1 receptor agonists
If you have been hearing about Ozempic (semaglutide) becoming available as a generic medication, you may be wondering what it means for your diabetes care
Certain factors may increase susceptibility to burping and related gastrointestinal symptoms, including: Rapid dose escalation (not following the recommended titration schedule) Concurrent use of other medications affecting gut motility (such as opioids or anticholinergics) Pre-existing gastrointestinal conditions such as gastroparesis or gastroesophageal reflux disease (GERD) Dietary habits that promote gas production Gastrointestinal adverse effects, including burping, are generally more common and pronounced at higher doses, which explains the higher rates observed with Wegovy compared to Ozempic
The product is not intended for children
To reference wikipedia, research began in the early 1960s which showed that in rats, administration of -MSH caused sexual arousal
It's either counterfeit or illegal substances